Publikasjoner - Legemidler ved graviditet og amming
Avdeling for klinisk farmakologi
• Galbally M, Ryan J, van IJzendoorn M, Watson SJ, Spigset O, Lappas K, Saffery R, de Kloet R, Lewis AJ. Maternal depression, antidepressant use and placental oxytocin receptor DNA methylation: findings from the MPEWS study. Psychoneuroendocrinology 2018; 90: 1-8.
https://www.ncbi.nlm.nih.gov/pubmed/?term=29407512
• Husebye ESN, Gilhus NE, Riedel B, Spigset O, Daltveit AK, Bjørk MH. Verbal abilities in children of mothers with epilepsy. Association to maternal folate status. Neurology 2018; 91: e811-e821.
https://www.ncbi.nlm.nih.gov/pubmed/?term=30068633
• Reimers A, Helde G, Becser Andersen N, Aurlien D, Surlien Navjord E, Haggag K, Christensen J, Lillestølen KM, Nakken KO, Brodtkorb E. Zonisamide serum concentrations during pregnancy. Epilepsy Res 2018; 144: 25-29.
https://www.ncbi.nlm.nih.gov/pubmed/?term=29751353
• Lupattelli A, Spigset O, Nordeng H. Learning the effects of psychotropic drugs during pregnancy using real-world safety data: a paradigm shift towards modern pharmacovigilance. Int J Clin Pharm 2018; 40: 783-6.
https://www.ncbi.nlm.nih.gov/pubmed/?term=29948744
• Westin AA, Reimers A, Spigset O. Skal gravide ha høyere eller lavere legemiddeldoser? Tidsskr Nor Legeforen 2018; 138: 1624-7.
https://tidsskriftet.no/2018/10/klinisk-oversikt/skal-gravide-ha-lavere-eller-hoyere-legemiddeldoser
• Christensen J, Reimers A. Management of pregnant women with epilepsy who use lamotrigine. Epilepsy Res 2018; 140: 198.
https://www.ncbi.nlm.nih.gov/pubmed/?term=29395497
• Westin AA, Brekke M, Molden E, Skogvoll E, Castberg I, Spigset O. Treatment with antipsychotics in pregnancy: changes in drug disposition. Clin Pharmacol Ther 2018; 103: 477-84.
https://www.ncbi.nlm.nih.gov/pubmed/?term=28643331
• Bjørk M, Riedel B, Spigset O, Veiby G, Kolstad E, Dahltveit AK, Gilhus NE. Folic acid during pregnancy and risk of autistic traits in children exposed to antiepileptic drugs in utero. JAMA Neurology 2018; 75: 160-8.
https://www.ncbi.nlm.nih.gov/pubmed/?term=29279889
• Westin AA, Brekke M, Molden E, Skogvoll E, Castberg I, Spigset O. Changes in drug disposition of lithium during pregnancy: a retrospective observational study of patient data from two routine therapeutic drug monitoring services in Norway. BMJ Open 2017; 7: e015738.
https://www.ncbi.nlm.nih.gov/pubmed/?term=28249852
• Westin AA, Brekke M, Molden E, Skogvoll E, Castberg I, Spigset O. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: changes in drug disposition. PLOS One 2017; 12: e0181082.
https://www.ncbi.nlm.nih.gov/pubmed/?term=28708853
• Lupattelli A, Wood M, Lapane K, Spigset O, Nordeng H. Risk of preeclampsia after gestational exposure to selective serotonin reuptake inhibitors and other antidepressants: a study from the Norwegian Mother and Child cohort study. Pharmacoepidemiol Drug Saf 2017; 26: 1266-76.
https://www.ncbi.nlm.nih.gov/pubmed/?term=28815791
• Galbally M, Spigset O, Johnson AR, Kohan R, Lappas K, Lewis AJ. Neonatal adaptation following intrauterine antidepressant exposure: assessment, drug assay levels, and infant development outcomes. Pediatric Res 2017; 82: 806-13.
https://www.ncbi.nlm.nih.gov/pubmed/?term=28665925
• Nezvalova-Henriksen K, Wood M, Spigset O, Nordeng H. Effect of prenatal ibuprofen exposure on birth weight and gestational age: a population-based sibling study. PLoS One 2016; 11: e0166971.
https://www.ncbi.nlm.nih.gov/pubmed/27936000
• Nezvalova-Henriksen K, Spigset O, Brandlistuen RE, Ystrøm E, Koren G, Nordeng H. Effect of prenatal selective serotonin reuptake inhibitor (SSRI) exposure on birth weight and gestational age: a sibling-controlled cohort study. Int J Epidemiol 2016; 45: 2018-29.
https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyw049
• Spigset O, Nordeng H. Safety of psychotropic drugs in pregnancy and breastfeeding. In: Spina E, Trifirò G (eds). Pharmacovigilance in psychiatry. Cham, Switzerland: Springer, 2016, pp. 299-319. ISBN 978-3-319-24739-7.
• Nordeng H, Kaplan YC, Spigset O. Antipsychotics and breastfeeding. In: Uguz F (ed.). Psychiatric disorders during the postpartum period. Nova Publishers, Hauppauge NY, 2016, pp. 143-151. ISBN 978-1-634-84579-3.
• Westin AA, Brekke M, Molden E, Skogvoll E, Castberg I, Spigset O. Changes in drug disposition of lithium during pregnancy: a retrospective observational study of patient data from two routine therapeutic drug monitoring services in Norway. BMJ Open 2017; 7: e015738.
http://bmjopen.bmj.com/content/7/3/e015738.long
• Lupattelli A, Spigset O, Björnsdottir I, Hameen-Antilla K, Mårdby AC, Panchaud A et al. Patterns and factors associated with low adherence to psychotropic medications during pregnancy – a cross-sectional, multinational web-based study. Depess Anxiety 2015; 32; 426-36. http://www.ncbi.nlm.nih.gov/pubmed/?term=25703355
• Amundsen S, Nordeng H, Nezvalová-Henriksen K, Stovner LJ, Spigset O. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nature Rev Neurol 2015; 11: 209-19.
http://www.ncbi.nlm.nih.gov/pubmed/?term=25776823
• Lupattelli A, Spigset O, Torgersen L, Zervas S, Hatle M, Reichborn-Kjennerud T, Bulik CM, Nordeng H. Medication use before, during and after pregnancy among women with eating disorders: a study from the Norwegian Mother and Child Cohort Study. Plos One 2015; 10: e0133045. http://www.ncbi.nlm.nih.gov/pubmed/?term=26200658